Bayer AG Files Patent Infringement Lawsuit Against BioNTech Amid Acquisition of CureVac
Bayer AG's Monsanto unit has initiated a patent infringement lawsuit against BioNTech SE and Pfizer, alleging unauthorized use of mRNA stabilization methods, and is seeking compensation from the revenues of the COVID-19 vaccine Comirnaty. Meanwhile, BioNTech has finalized its acquisition of CureVac, bolstering its oncology and mRNA capabilities, despite a recent drop in its share price. The company reported $16.7 billion in liquid assets as it prepares for an upcoming announcement on strategic priorities.
Theia Market Signal Identification - AI Assisted
Bayer AG's Monsanto unit has filed a patent infringement lawsuit against BioNTech SE and Pfizer in Delaware, claiming the companies used patented methods for mRNA stabilization originally developed in the 1980s. Bayer seeks compensation and royalties on past and future revenues from the COVID-19 vaccine Comirnaty, which has generated over $93 billion in sales.
Concurrently, BioNTech has completed its acquisition of CureVac, effective January 6, 2026, enhancing its oncology division and mRNA capabilities. BioNTech shares dropped nearly 11% recently, pricing at €85.70, but the company reported $16.7 billion in liquid assets at the end of Q3 2025, providing a strong financial foundation for both the acquisition and legal defense. Investors await BioNTech's strategic priorities announcement on January 13, 2026.
Comments